<p>Dongyao Pharmaceutical-B (01875.HK) announced that for the nine months ending in September, operating revenue was 622 million RMB, a year-on-year decrease of 23%, mainly due to intensified market competition for self-developed products. It recorded a loss of 3.37 million RMB, compared to a net profit of 35.4 million RMB in the same period last year, turning from profit to loss</p>

01875

<p>Dongyao Pharmaceutical - B announced that for the nine months ending in September, the operating revenue was 622 million RMB, a year-on-year decrease of 23%, mainly due to intensified market competition for self-developed products. It recorded a loss of 3.37 million RMB, compared to a net profit of 35.4 million RMB in the same period last year, turning from profit to loss</p>

In the first nine months, Dongyao Pharmaceutical reported a loss of 3.37 million RMB